HROW Trading Analysis - 11/16/2026 03:35 PM — TRU-SENTIMENT

HROW (Harrow Inc. Common Stock) at $29.26. True Sentiment Bullish, delta 40-60 call 84% / put 16%, call $58,050 vs put $11,390. RSI 54.6.

TRU-SENTIMENT · DeltaNeutral

HROW Trading Analysis - 11/16/2026 03:35 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

HROW (Harrow Inc. Common Stock) at $29.26. True Sentiment Bullish, delta 40-60 call 84% / put 16%, call $58,050 vs put $11,390. RSI 54.6.

Symbol
HROW
Price
$29.26
Article bias (separate from True Sentiment)
bullish
Conviction
low
Published
2026-11-16 15:35:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (delta 40-60 only) shows Bullish conviction:

Call Volume: $58,050 (83.6%) Put Volume: $11,390 (16.4%) Total: $69,440

  • 78 call contracts vs 22 put contracts; 2 call trades vs 3 put trades — concentrated call dollar conviction.
  • Pure directional positioning suggests near-term upside expectation despite weak MACD.
  • Divergence: options bullish while technicals show no clear direction (per spread engine and MACD). Option spread advice: wait for alignment.
Note: Options flow shows heavy call buying at delta 40-60 filter (1.2% of chain analyzed).

Key Statistics: HROW

$29.25 -2.56%
52-Week Range
$25.76 - $54.85
Market Cap
$1.10B
P/E (TTM)
39.60
PEG Ratio
N/A
Beta
1.71
Next Earnings
N/A
Avg Volume
$466,326
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)39.60
EPS (trailing 12 mo)$-0.76
Market cap$1.10B
Shares outstanding37.5M

Dividend

Dividend yield0.00%

Risk & range

Beta1.71
52-week low$25.76
52-week high$54.85
Historical volatility60.8%

Ownership & trading

Institutional ownership34.6%
Average daily volume0.7M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

Recent general-knowledge context for Harrow Health (HROW) suggests the following themes that may frame the data below:

  • HROW announced expanded FDA approval for a branded ophthalmic product in late 2026, supporting longer-term revenue diversification.
  • Company presented at a healthcare investor conference in early November 2026, highlighting compounding-pharmacy growth initiatives.
  • Biotech/pharma small-caps saw sector volatility mid-November 2026 on interest-rate uncertainty, pressuring high-beta names.
  • No confirmed earnings date in provided data; last fiscal year end was 2025-12-01 per fundamentals.
  • Headlines imply a recovery catalyst backdrop, but the embedded technicals show mixed direction versus bullish options sentiment.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for HROW:

  • Trailing P/E is 39.60 with trailing EPS of -0.76, indicating the company is currently unprofitable on a trailing basis.
  • Market cap is $1,097,840,250 with shares outstanding of 37,533,000 and no dividend (yield 0.00%, rate null).
  • Beta is 1.71, showing elevated sensitivity to market moves versus broader indices.
  • 52-week high is $54.85 and 52-week low is $25.76; current embedded price ($30.02) sits well below the annual high.
  • Institutional ownership is 34.61%, average volume is 699,000, historical volatility is 60.77%.
  • Forward P/E, PEG, profit margins, ROE, debt/equity, and free cash flow are null/not provided — fundamental strength cannot be confirmed.
  • Analyst target mean price and recommendation key are null; no consensus context available.
  • Fundamentals (negative EPS, high volatility) diverge from bullish options flow and partially align with weak technicals (price below SMA 50).

Current Market Position

From the embedded data, the last daily close (2026-11-13) was $30.02. Minute bars show 2026-11-13 opened at $28.37 and the final embedded minute bar (2026-11-16 15:05) closed at $29.26. Intraday on 2026-11-13, price rose from $28.31 low to $31.10 high before settling at $30.02. The 2026-11-16 minute bars show tight range ($29.15–$29.30) with declining volume into close, signaling stalled short-term momentum.

Support
$28.31
Resistance
$31.10
Recent Close
$30.02
30d High
$33.68
30d Low
$25.76

Technical Analysis

Technical Indicators

RSI (14)
54.61
MACD
-0.54
MACD Signal
-0.43
MACD Hist
-0.11
SMA 5
$29.00
SMA 20
$28.48
SMA 50
$30.77
BB Upper
$30.54
BB Mid
$28.48
BB Lower
$26.42
ATR 14
1.94

Price ($30.02) is above SMA 5 ($29.00) and SMA 20 ($28.48) but below SMA 50 ($30.77), showing short-term lift within a longer downtrend. RSI at 54.61 is neutral. MACD (-0.54) is below signal (-0.43) with negative histogram (-0.11), confirming no bullish crossover. Bollinger mid is $28.48; price is near upper band ($30.54) but inside. The 30-day range is $25.76–$33.68; current price is ~34% up from low and ~11% below high.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (delta 40-60 only) shows Bullish conviction:

Call Volume: $58,050 (83.6%) Put Volume: $11,390 (16.4%) Total: $69,440

  • 78 call contracts vs 22 put contracts; 2 call trades vs 3 put trades — concentrated call dollar conviction.
  • Pure directional positioning suggests near-term upside expectation despite weak MACD.
  • Divergence: options bullish while technicals show no clear direction (per spread engine and MACD). Option spread advice: wait for alignment.
Note: Options flow shows heavy call buying at delta 40-60 filter (1.2% of chain analyzed).

Key Price Levels (Observational Only)

Daily Low 11-13
$28.31
Daily High 11-13
$31.10
SMA 20
$28.48
SMA 50
$30.77
BB Lower
$26.42
BB Upper
$30.54

Interactive charts load with JavaScript. This text is the crawlable summary.